RECURSION PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 3.06 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 751.15K shares, a 27.22% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 711.12K shares, a 340.96% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was 340.20K shares, a 71.01% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-03-31 was 1.25M shares, a 602.27% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 3.06M shares, a 170.69% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 1.13M shares, a 22.68% decline from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.46M shares, a 2.24% decline from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 1.49M shares, a 17.92% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 751.15K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 1.46M shares derived: sum of 2 quarters · filed 2026-02-25 | 1.80M shares derived: sum of 3 quarters · filed 2026-02-25 | 3.06M shares 10-K · filed 2026-02-25 |
| 2025-09-30 | 711.12K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 1.05M shares derived: sum of 2 quarters · filed 2025-11-05 | 2.31M shares 10-Q · filed 2025-11-05 | 2.90M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 340.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 1.59M shares 10-Q · filed 2025-08-05 | 2.18M shares derived: sum of 3 quarters · filed 2025-08-05 | 2.35M shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 1.25M shares 10-Q · filed 2025-05-05 | 1.84M shares derived: sum of 2 quarters · filed 2025-05-05 | 2.01M shares derived: sum of 3 quarters · filed 2025-05-05 | 2.20M shares derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | 590.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | 751.70K shares derived: sum of 2 quarters · filed 2025-02-28 | 950.63K shares derived: sum of 3 quarters · filed 2025-02-28 | 1.13M shares 10-K · filed 2025-02-28 |
| 2024-09-30 | 161.26K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 360.19K shares derived: sum of 2 quarters · filed 2024-11-06 | 538.80K shares 10-Q · filed 2024-11-06 | 1.09M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 198.93K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 377.54K shares 10-Q · filed 2024-08-08 | 927.30K shares derived: sum of 3 quarters · filed 2024-08-08 | 1.07M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 178.61K shares 10-Q · filed 2024-05-09 | 728.37K shares derived: sum of 2 quarters · filed 2024-05-09 | 869.86K shares derived: sum of 3 quarters · filed 2024-05-09 | 968.01K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 549.76K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 691.25K shares derived: sum of 2 quarters · filed 2024-02-29 | 789.40K shares derived: sum of 3 quarters · filed 2024-02-29 | 1.46M shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 141.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 239.64K shares derived: sum of 2 quarters · filed 2023-11-09 | 910.76K shares 10-Q · filed 2023-11-09 | 969.65K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 98.15K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 769.26K shares 10-Q · filed 2023-08-08 | 828.15K shares derived: sum of 3 quarters · filed 2023-08-08 | 1.08M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 671.12K shares 10-Q · filed 2023-05-08 | 730.01K shares derived: sum of 2 quarters · filed 2023-05-08 | 981.14K shares derived: sum of 3 quarters · filed 2023-05-08 | 1.82M shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 58.89K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | 310.02K shares derived: sum of 2 quarters · filed 2023-02-27 | 1.15M shares derived: sum of 3 quarters · filed 2023-02-27 | 1.49M shares 10-K · filed 2023-02-27 |
| 2022-09-30 | 251.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 1.09M shares derived: sum of 2 quarters · filed 2022-11-08 | 1.44M shares 10-Q · filed 2022-11-08 | 1.50M shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 837.69K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 1.18M shares 10-Q · filed 2022-08-09 | 1.25M shares derived: sum of 3 quarters · filed 2022-08-09 | 1.77M shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 346.32K shares 10-Q · filed 2022-05-10 | 410.05K shares derived: sum of 2 quarters · filed 2022-05-10 | 932.62K shares derived: sum of 3 quarters · filed 2022-05-10 | 1.23M shares derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | 63.73K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | 586.30K shares derived: sum of 2 quarters · filed 2022-03-23 | 882.43K shares derived: sum of 3 quarters · filed 2022-03-23 | 1.27M shares 10-K · filed 2022-03-23 |
| 2021-09-30 | 522.57K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 818.70K shares derived: sum of 2 quarters · filed 2021-11-10 | 1.20M shares 10-Q · filed 2021-11-10 | |
| 2021-06-30 | 296.13K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | 680.67K shares 10-Q · filed 2021-08-13 | ||
| 2021-03-31 | 384.54K shares 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |